Labosud SELAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Labosud SELAS - overview
Established
2009
Location
Montpellier, -, France
Primary Industry
Biotechnology
About
Labosud SELAS is a French medical biology laboratory specializing in diagnostic testing and patient care, committed to high-quality medical diagnostics across various healthcare sectors. Founded in 2009, Labosud SELAS operates as a medical biology laboratory, providing diagnostic services primarily in the south of France. The company is headquartered in Montpellier, France. In November 2020, Ardian negotiated the acquisition of a minority stake in the company from Groupe Inovie, which was finalized in March 2021.
The company has completed one deal as of the latest record in 2020. INOVIE Labosud specializes in medical biology laboratory services, focusing on diagnostic testing and patient care. The group has consolidated several laboratories across southern France, ensuring independence and innovation. Their comprehensive range of biological tests serves nearly 15,000 patients daily across approximately 100 local laboratories, with major technical platforms in Béziers, Nîmes, and Montpellier.
The services support both healthcare professionals and patients, addressing essential health needs. For the year 2022, INOVIE Labosud reported a revenue of EUR 201,093,611. 70 and an EBITDA of EUR 57,933,448. 90.
Their revenue model operates through both B2B transactions and direct-to-consumer services, facilitating diagnostic tests primarily reimbursed by healthcare providers, thus supporting over 70% of medical diagnostics in the region. The company aims to leverage its recent funding to enhance its diagnostic services and expand its reach. Following the minority stake acquisition by Ardian in 2021, Labosud SELAS is focusing on launching new diagnostic products and exploring further geographic expansion within the French healthcare market. The insights gained from this strategic partnership will be utilized to innovate testing solutions and improve operational efficiencies as they aim to meet the growing healthcare demands by 2023.
Current Investors
Ardian
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories
Website
www.labosud.fr
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Labosud SELAS - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 120,220,486 | 124,539,608 | 125,233,020 | 129,613,370 | 168,424,996 | 221,680,275 | - | - | - |
| % Revenue Growth (YoY) | - | 3.6% | 0.6% | 3.5% | 29.9% | 31.6% | - | - | - |
| EBITDA (USD) | 14,188,287 | 14,188,802 | 12,938,209 | 16,194,876 | 29,255,038 | 82,281,591 | - | - | - |
| Operating Income (USD) | 11,251,808 | 10,896,996 | 9,323,073 | 12,525,159 | 25,552,185 | 76,949,760 | - | - | - |
| Operating Margin | 9.4% | 8.7% | 7.4% | 9.7% | 15.2% | 34.7% | - | - | - |
| % EBITDA Margin | 11.8% | 11.4% | 10.3% | 12.5% | 17.4% | 37.1% | - | - | - |
| NET Income (USD) | 8,045,024 | 10,628,759 | 13,234,892 | 18,405,465 | 33,455,628 | 218,908,078 | - | - | - |
| % Net Margin | 6.7% | 8.5% | 10.6% | 14.2% | 19.9% | 98.7% | - | - | - |
Labosud SELAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Biofutur SELARL | - | ||||||||
| Buyout | Completed | Labosud SELAS | - | ||||||||
| Trade Sale | Completed | Laboudie & Associates | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.